During the corresponding time, Cardiff Oncology Inc saw a revenue deteriorated by -14.05 % year on year, sequentially revenue grew by 153.66 %. While revenue at the Cardiff Oncology Inc 's corporate clients
Cardiff Oncology Inc's Comment on Sales, Marketing and Customers
Pharmaceutical manufacturers market, sell, and distribute drug and biologic products to customers including prescribers, purchasers, and formulary managers. Their interactions are regulated by laws such as the federal Anti-Kickback Statute, the Federal False Claims Act, and the Health Insurance Portability and Accountability Act (HIPAA). These regulations govern relationships with customers and healthcare programs, including Medicare, Medicaid, other federally financed healthcare programs, and private third-party payors.
At the recent American Society of Clinical Oncology (ASCO) 2025 meeting, Cardiff Oncology presented promising results from an investigator-initiated Phase 1b clinical trial evaluating the combination of onvansertib and paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). This aggressive form of breast cancer, known for its resistance to standard therapies and poor prognosis, has propelled researchers to seek innovative treatment approaches. The data showcased at ASCO offers renewed hope for patients battling this challenging disease. The Significance of the Trials Triple-negative breast cancer is characterized by the absence of estrogen receptors, progesterone receptors, and the HER2...
In a recent announcement, Cardiff Oncology unveiled the results for the fourth quarter and full year of 2023, along with an exciting business update. The company reported substantial progress towards their new lead program in the treatment of RAS-mutated metastatic colorectal cancer (mCRC), made possible through collaboration with the FDA and clinical execution from Pfizer Ignite. This article aims to present an overview of the key findings and developments outlined in the two related articles, shedding light on the significance of such advancements in the field of oncology.1. Positive Results from Fourth Quarter and Full Year 2023:Cardiff Oncology s recently disclosed financial results for the fourth quart...
Cardiff Oncology Inc’s Comment on Sales, Marketing and Customers
Pharmaceutical manufacturers market, sell, and distribute drug and biologic products to customers including prescribers, purchasers, and formulary managers. Their interactions are regulated by laws such as the federal Anti-Kickback Statute, the Federal False Claims Act, and the Health Insurance Portability and Accountability Act (HIPAA). These regulations govern relationships with customers and healthcare programs, including Medicare, Medicaid, other federally financed healthcare programs, and private third-party payors.
Sources:
Cardiff Oncology Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Cardiff Oncology Inc’s corporate clients.
For your research, we’ve provided 9 tables on Cardiff Oncology Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
